First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial
The PENPACT-1 (PENTA 9/PACTG 390) Study Team
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: An open-label, randomised phase 2/3 trial'. Together they form a unique fingerprint.